ClinicalTrials.gg

Program

IBI355

A development code. Also written as “Part A - IBI355”.

Its studies are mostly in Sjogren's Syndrome, led by Innovent Biologics.

Furthest: phase 2, since Sep 13, 20264 company-led studies, 1 open or runningNext primary completion: Nov 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics41 open or runningphase 2since Sep 13, 2026Oct 26, 2023Nov 1, 2027phase 2 · NCT07836660

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 26, 2023First study: phase 1 study in Healthy SubjectsFirst studyNCT06110338 · 53 enrolled · China
  2. May 11, 2024Phase 1 study in HealthyNCT06416787 · 32 enrolled · China
  3. Jun 26, 2024Phase 1 study in Primary Sjögren's SyndromeNCT06484855 · 30 enrolled · China
  4. Sep 13, 2026Phase 2 study in Sjogren's SyndromePhase 2 reachedNCT07836660 · 198 planned · China

Ahead

  1. Nov 1, 2027Primary completion: phase 2 study in Sjogren's SyndromeNCT07836660

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07836660Sjogren's Syndrome · China2Not yet recruitingNov 1, 2027198
NCT06484855Primary Sjögren's Syndrome · China1CompletedJun 21, 202530
NCT06416787Healthy · China1CompletedFeb 26, 202532
NCT06110338Healthy Subjects · China1CompletedSep 20, 202453

How it is read

Names in the registry

  • “IBI355”, 3 entries
  • “Part A - IBI355”, 1 entry

Codes read as this program: IBI355.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.